Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Uma perspectiva global sobre os dados emergentes da terapia com inibidor de BTK para LLC e LCM recidivantes/refratários em 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

1.00
Personalized Treatment Options From 5 Experts for People With CLL

Content Format:

Tool

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL in 2022

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Expert Guidance for the Treatment of CLL

Content Format:

Tool

Credit Type:

--

Credits:

--
Nos réflexions sur les implications des nouvelles données concernant la LLC et le LCM après l’ASCO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Unsere Überlegungen zu den Auswirkungen der neuen Daten zu CLL und MCL von der Jahrestagung der ASCO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Le nostre considerazioni riguardo alle implicazioni dei nuovi dati su LLC e MCL emersi dallASCO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Nossas reflexões sobre as Implicações dos novos dados em LLC e LCM da ASCO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Reflexiones sobre las novedades sobre LLC y LCM presentadas en ASCO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Our Thoughts on the Implications of New Data in CLL and MCL From ASCO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Podcast Pearls: Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Content Format:

PDF

Credit Type:

--

Credits:

--
Addressing Evolving Educational Needs on BTK Inhibitor Therapies in CLL/SLL and MCL

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.00
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
BTK Inhibitor Therapies in CLL/SLL and MCL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
ExpressPoints: BTK Inhibitor Therapies in CLL/SLL and MCL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Expert Perspectives on Key New Evidence in CLL Therapy

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Answers to Frequently Asked Questions on State-of-the-Art Management of CLL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
ExpressPointsGuideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

Content Format:

Slideset

Credit Type:

--

Credits:

--
State of the Art Management in Relapsed/Refractory CLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
Ibrutinib Plus Rituximab and the Expanding Therapeutic Toolbox for Previously Untreated CLL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimal Selection of New Molecules as Frontline Treatment of Chronic Lymphocytic Leukemia

Content Format:

Slideset Download

Credit Type:

--

Credits:

--